Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06592924 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Study acronym: TRIPLE-SWITCH
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 368 → 395 locationsv14
  2. Trial sites expanded: 340 → 368 locations
    • Eligibility criteria expanded, about 162 words
    v13
  3. Study sites: 340 to 368v12
  4. Trial sites expanded: 310 → 340 locationsv11
  5. Re-verified, no change to tracked fieldsv10
Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 274 to 310v9
  2. Study sites: 1 to 274v8
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 30, 2025 to May 28, 2025
    v7
  4. Start date: Mar 30, 2025 to May 30, 2025v6
  5. Start date: Jan 15, 2025 to Mar 30, 2025v5
  6. Study title shortened, about 5 wordsv4
  7. Collaborators: 3 to 4v3
  8. Study title expanded, about 7 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Trial Details
NCT Number NCT06592924
Lead Sponsor Canadian Cancer Trials Group
Collaborators: ECOG-ACRIN Cancer Research Group, NRG Oncology, Alliance for Clinical Trials in Oncology, SWOG Cancer Research Network
Conditions
(from sponsor)		 Prostate Cancer (Adenocarcinoma)
Related terms Adenocarcinoma, Prostatic Neoplasms
Enrollment 830 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov